MC4 receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-12-23. Numbers and descriptions here follow the published literature rather than marketing material.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
=== November === 1 November – The Commissioner for Ethical Standards in Public Life in Scotland finds SNP councillor Kairin van Sweeden in breach of the code of conduct for calling a political opponent a "New Scot" during a meeting of Aberdeen City Council in October 2023. 2 November – A 74-year-old man receives fatal injuries after being struck by a bus in Edinburgh's Cowgate. The following day, Police Scotland ask members of the public to stop sharing graphic images of the incident on social media. 3 November – Police Scotland say they have received a fresh allegation concerning a non-recent sexual assault against former First Minister Alex Salmond. 5 November – Senior consultants in Scotland have voted to accept a 10.5% pay rise that will see them earn between £10,500 and £13,500 extra each year, and which will be backdated to 1 April 2024. A waste management company is to sue the Scottish Government for £170m over the failed bottle return scheme. Bonfire Night disturbance breaks out in parts of Edinburgh, with missiles such as bricks, bottles and fireworks thrown at police. 6 November – Police Scotland say they have made 19 arrests following disturbances over Halloween and Bonfire Night. 8 November – The death certificate of Susan McGowan, a 58-year-old nurse from North Lanarkshire who died in September, has linked her death with the use of the weight loss drug tirzepatide (known under the brand name Mounjaro), which was recently approved for use on the NHS; it is reported to be the first UK death linked to the drug's use.
==== Superficial ==== Superficial fascia is the lowermost layer of the skin in nearly all of the regions of the body, that blends with the reticular dermis layer. It is present on the face, over the upper portion of the sternocleidomastoid, at the nape of the neck and overlying the breastbone. It consists mainly of loose areolar and fatty adipose connective tissue and is the layer that primarily determines the shape of a body. In addition to its subcutaneous presence, superficial fascia surrounds organs, glands and neurovascular bundles, and fills otherwise empty space at many other locations. It serves as a storage medium of fat and water; as a passageway for lymph, nerve and blood vessels; and as a protective padding to cushion and insulate. Superficial fascia is present, but does not contain fat, in the eyelid, ear, scrotum, penis and clitoris. Due to its viscoelastic properties, superficial fascia can stretch to accommodate the deposition of adipose that accompanies both ordinary and prenatal weight gain. After pregnancy and weight loss, the superficial fascia slowly reverts to its original level of tension.
The ability to create precise and carefully controlled chemoattractant gradients makes microfluidics the ideal tool to study motility, chemotaxis and the ability to evolve / develop resistance to antibiotics in small populations of microorganisms and in a short period of time. These microorganisms including bacteria and the broad range of organisms that form the marine microbial loop, responsible for regulating much of the oceans' biogeochemistry. Microfluidics has also greatly aided the study of durotaxis by facilitating the creation of durotactic (stiffness) gradients.
== Function == Alpha 2-antiplasmin serves as the primary physiological inhibitor of plasmin, the key enzyme responsible for fibrin degradation during fibrinolysis. By rapidly forming a covalent complex with plasmin, α2AP prevents excessive breakdown of fibrin clots, thereby maintaining hemostatic balance. In addition to direct inhibition, α2AP interferes with the binding of plasminogen to fibrin, further regulating the initiation of fibrinolysis. During clot formation, α2AP is cross-linked to fibrin by activated factor XIII, which increases the resistance of the clot to lysis and enhances clot stability. This function is critical in preventing premature clot dissolution, but elevated levels of α2AP have been associated with increased risk of thrombotic events, such as stroke and myocardial infarction, due to impaired fibrinolysis. Conversely, α2AP deficiency leads to increased susceptibility to bleeding because of uncontrolled plasmin activity and rapid clot breakdown. Thus, α2AP is essential for fine-tuning the balance between clot formation and dissolution, making it a potential therapeutic target in both thrombotic and bleeding disorders.
Sources: en.wikipedia.org
==== Hungary ==== In 1994, 265 mummified bodies were found in the crypt of a Dominican church in Vác, Hungary from the 1729–1838 period. The discovery proved to be scientifically important, and by 2006 an exhibition was established in the Museum of Natural History in Budapest. Unique to the Hungarian mummies are their elaborately decorated coffins, with no two being exactly alike.
=== Physical activity and weight reduction === Weight loss of ~7–10% over 6–12 months improves BP, lipids, and insulin sensitivity. Public-health guidance advises ≥150 min/week moderate aerobic activity (or 75 min vigorous) plus muscle-strengthening ≥2 days/week.
=== Metabolism === The metabolism of progesterone is rapid and extensive, and it occurs mainly in the liver, though enzymes that metabolize progesterone are also expressed widely in the brain, skin, and various other extrahepatic tissues. Progesterone has an elimination half-life of only approximately five minutes in circulation. The metabolism of progesterone is complex, and it may form as many as 35 different unconjugated metabolites when it is ingested orally. Progesterone is highly susceptible to enzymatic reduction via reductases and hydroxysteroid dehydrogenases because of its double bond (between the C4 and C5 positions) and its two ketones (at the C3 and C20 positions). The major metabolic pathway of progesterone is reduction by 5α-reductase and 5β-reductase, into the dihydrogenated 5α-dihydroprogesterone and 5β-dihydroprogesterone, respectively. This is followed by the further reduction of these metabolites via 3α-hydroxysteroid dehydrogenase and 3β-hydroxysteroid dehydrogenase into the tetrahydrogenated allopregnanolone, pregnanolone, isopregnanolone, and epipregnanolone. Subsequently, 20α-hydroxysteroid dehydrogenase and 20β-hydroxysteroid dehydrogenase reduce these metabolites to form the corresponding hexahydrogenated pregnanediols (eight different isomers in total), which are then conjugated via glucuronidation and/or sulfation, released from the liver into circulation, and excreted by the kidneys into the urine.
Regardless of their usage, these substances gained popularity and began to be documented, information being passed down generations. There are Hindu poems dated back to around 2000 to 1000 BCE that spoke of performance enhancers, ingredients, and usage tips. Chinese texts date back to 2697 to 2595 BC. Roman and Chinese cultures documented their belief in aphrodisiac qualities in animal genitalia, while Egyptians wrote tips for treating erectile dysfunction. In post-classical West Africa, a volume titled Advising Men on Sexual Engagement with Their Women from the Timbuktu Manuscripts acted as a guide on aphrodisiacs and infertility remedies. It offered advice to men on "winning back" their wives. According to Hammer, "At a time when women’s sexuality was barely acknowledged in the West, the manuscript, a kind of Baedeker to orgasm, offered tips for maximizing sexual pleasure on both sides." Ambergris, yohimbine, horny goat weed, ginseng, alcohol, toads from the genus Bufo, and certain foods are recorded throughout these texts as possessing aphrodisiac qualities. While many plants, extracts, or manufactured hormones have been proposed as aphrodisiacs, there is little high-quality clinical evidence of their efficacy or long-term safety. In 2020, Brian Earp and Julian Savulescu published a philosophy book titled Love Drugs: The Chemical Future of Relationships (UK title Love Is the Drug: The Chemical Future of Our Relationships).
Although a systematic survey has not been done to identify all chemosynthetic communities in the Gulf of Mexico, there is evidence indicating that many more such communities may exist. The depth limits of discoveries probably reflect the limits of exploration (lack of submersibles capable of depths over 1,000 metres (3,300 feet)). MacDonald et al. (1993 and 1996) have analyzed remote-sensing images from space that reveal the presence of oil slicks across the north-central Gulf of Mexico. Results confirmed extensive natural oil seepage in the Gulf of Mexico, especially in water depths greater than 1,000 metres (3,300 feet). A total of 58 additional potential locations were documented where seafloor sources were capable of producing perennial oil slicks. Estimated seepage rates ranged from 4 bbl/d (0.64 m3/d) to 70 bbl/d (11 m3/d) compared to less than 0.1 bbl/d (0.016 m3/d) for ship discharges (both normalized for 1,000 mi2 (640,000 ac)). This evidence considerably increases the area where chemosynthetic communities dependent on hydrocarbon seepage may be expected. The densest aggregations of chemosynthetic organisms have been found at water depths of around 500 metres (1,600 feet) and deeper. The best known of these communities was named Bush Hill by the investigators who first described it. It is a surprisingly large and dense community of chemosynthetic tube worms and mussels at a site of natural petroleum and gas seepage over a salt diapir in Green Canyon Block 185.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.